Cargando…
A comprehensive population-based study comparing the phenotype and genotype in a pretherapeutic screen of dihydropyrimidine dehydrogenase deficiency
BACKGROUND: Pretherapeutic screening for dihydropyrimidine dehydrogenase (DPD) deficiency is recommended or required prior to the administration of fluoropyrimidine-based chemotherapy. However, the best strategy to identify DPD-deficient patients remains elusive. METHODS: Among a nationwide cohort o...
Autores principales: | Pallet, Nicolas, Hamdane, Salma, Garinet, Simon, Blons, Hélène, Zaanan, Aziz, Paillaud, Elena, Taieb, Julien, Laprevote, Olivier, Loriot, Marie-Anne, Narjoz, Céline |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7462856/ https://www.ncbi.nlm.nih.gov/pubmed/32595208 http://dx.doi.org/10.1038/s41416-020-0962-z |
Ejemplares similares
-
Quantitative impact of pre‐analytical process on plasma uracil when testing for dihydropyrimidine dehydrogenase deficiency
por: Maillard, Maud, et al.
Publicado: (2022) -
Role of Circulating Tumor DNA in Gastrointestinal Cancers: Current Knowledge and Perspectives
por: Moati, Emilie, et al.
Publicado: (2021) -
Concordance of Blood-Based and Normal Tissue-Based Dihydropyrimidine
Dehydrogenase (DPYD) Genotyping
por: Morelli, Cristina, et al.
Publicado: (2022) -
Dihydropyrimidine Dehydrogenase Deficiency: To Screen or Not to Screen?
por: Vogel, Wendy H., et al.
Publicado: (2020) -
Next-Generation Sequencing Targeted Panel in Routine Care for Metastatic Colon Cancers
por: Bayle, Arnaud, et al.
Publicado: (2021)